Helping you make informed decisions on investing, money, equities and personal finance. Seasoned investors or newbie traders, our financial education corner has something for all.
IPD, MX1 & MDR: Three ASX health tech stocks with strong revenue in 3Q
Aditi covers content focused on healthcare and food & beverages sectors. She has a post-graduate degree in Genetics and Plant Breeding with Biotechnology as her minor subject. She has two co-authored scientific research publications in peer-reviewed ...
Shwetambri Chauhan is a Sr. Research Editor at Kalkine Media. She comes with an experience of 11 years in secondary research and quality check. Besides, she has rich experience of working across different sectors and markets. Her professional experie...
Medical technologies assist healthcare professionals in diagnosing and treating patients with a higher level of accuracy and on time. The next generation of medical technologies holds great potential in advancing the entire health care industry.
This article will discuss three medical technology companies and their updates from the quarter ended 31 March 2022.
Do read: MX1, MDR, and OSX: Medical technology stocks from ASX
ImpediMed Limited, a medical software technology company, reported a strong turnaround in patient testing and sales in the month of March. Based in Australia, the company produces a range of FDA cleared, and CE Marked medical devices, including SOZO® for multiple indications including heart failure, lymphoedema, and protein-calorie malnutrition. These devices are sold in select markets globally. IPD has its operations in the US and Europe.
Major highlights of the March quarter
Do read: AGN, PYC, KZA: An insight into key highlights of healthcare therapeutics from March quarter
MedAdvisor is a world-class medication management platform that uses a highly automated and intuitive software system. It empowers patients to manage their medication and improve adherence in a simple way by connecting patients to tools and education materials from their preferred pharmacy.
MDR reported a 96.1% surge in 3Q FY22 YTD operating revenue compared to prior corresponding period.
The company has delivered more than 4.5 million COVID-19 vaccinations to date through its network of pharmacies.
Data source: Company update
Micro-X Ltd is a hi-tech company specialising in a range of products for the global health and security markets. The company has a production facility in Adelaide, Australia, and a growing technical and commercial team in Seattle to expand its business in the US.
Key achievements during the three-month period ended 31 March
Also read: NSB, FRE, MDR: Latest updates from 3 ASX healthcare penny stocks
Copyright © 2022 Kalkine Media Pty Ltd. All Rights Reserved.